Canaccord raised the firm’s price target on Alphatec (ATEC) to $25 from $20 and keeps a Buy rating on the shares. The firm said they posted another impressive quarter, this time beating consensus estimates by over 7% with both surgical revenue and EOS momentum while the company saw nearly 30% growth in surgical volume, 30% growth in established territories, and 26% growth in new surgeon users.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATEC:
- Alphatec price target raised to $24 from $20 at H.C. Wainwright
- Alphatec Reports Strong Q3 2025 Revenue Growth
- Alphatec up 22% at $19.86 after Q3 earnings beat and guidance raise
- Alphatec reports Q3 adjusted EPS 3c, consensus (2c)
- Alphatec raises FY25 revenue view to $760M from $742M, consensus $742.03M